Statistical analysis:
We compared the baseline characteristics between subjects who had a
history of use of ACEI/ARB those who didn’t use these medications using
the chi-square test and t-test (Table1). First, we performed a simple
logistic regression analysis to study the association between ICU
admission rates and the use of ACEI/ARBs. We then used a multivariate
logistic regression model to adjust for possible confounders including
age, sex, race, BMI, COPD, asthma, use of aldosterone antagonists, heart
failure, DM, and ESRD. Using the same methods, we studied the
association between COVID-19 mortality and the use of ACEI/ARB. We used
a Cox proportional hazards model to study the association between the
use of ACEI/ARB and 30 days-COVID-19 survival. We censored the time to
the event to 30 days. We first performed a univariate model and then
performed a multivariate-adjusted model. We adjusted for the same
possible confounders as those mentioned above.
R studio was used to analyze the data and a p-value of ≤0.05 was
considered statistically significant.